author-photo

David R. Staskin

Tufts University
Cornell University
NewYork–Presbyterian Hospital

226

Papers

4990

Citations

Citation Trend

Filter By

Papers (152) Sort By

Journal Conference Others

MP63-15 VIBEGRON FOR THE TREATMENT OF PATIENTS WITH DRY OVERACTIVE BLADDER: A SUBGROUP ANALYSIS FROM THE EMPOWUR TRIAL

2021 The Journal of Urology
Show All
- Source
- Cite
- Save
Citations (0)
Safety and Tolerability Results from the PILLAR Study: A Phase IV, Double-Blind, Randomized, Placebo-Controlled Study of Mirabegron in Patients ≥ 65 years with Overactive Bladder-Wet

2020 Drugs & Aging
Show All
- Source
- Cite
- Save
Citations (3)
PD21-02 EFFICACY OF ONCE-DAILY VIBEGRON 75 MG FOR OVERACTIVE BLADDER (OAB) IN OLDER PATIENTS: THE EMPOWUR RANDOMIZED, INTERNATIONAL, PHASE 3 STUDY

2020 The Journal of Urology
Show All
- Source
- Cite
- Save
Citations (1)
Vibegron Improves Quality-of-Life Measures in Patients With Overactive Bladder: Patient-Reported Outcomes From the EMPOWUR Study

2020 International Journal of Clinical Practice
Show All
- Source
- Cite
- Save
Citations (0)
Efficacy and Safety of Mirabegron versus Placebo Add-On Therapy in Men with Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Randomized, Phase 4 Study (PLUS).

2020 The Journal of Urology
Show All
- Source
- Cite
- Save
Citations (14)
Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR).

2020 BMC Geriatrics
Show All
- Source
- Cite
- Save
Citations (25)
Once-Daily Vibegron 75 mg for Overactive Bladder: Long-Term Safety and Efficacy From a Double-Blind Extension Study of the International Phase 3 Trial (EMPOWUR).

2020 The Journal of Urology
Show All
- Source
- Cite
- Save
Citations (3)
Efficacy, safety, and tolerability of mirabegron in patients aged ≥65 yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR)

2019 European Urology
Show All
- Source
- Cite
- Save
Citations (24)
LBA-02 INTERNATIONAL PHASE 3, DOUBLE-BLIND, PLACEBO- AND ACTIVE (TOLTERODINE)-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF VIBEGRON IN PATIENTS WITH SYMPTOMS OF OVERACTIVE BLADDER: EMPOWUR

2019 The Journal of Urology
Show All
- Source
- Cite
- Save
Citations (0)
Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo

2019 European Urology
Show All
- Source
- Cite
- Save
Citations (22)